In addition to a proprietary CAR targeting CD19, FT596 expresses a novel hnCD16 Fc receptor that has been modified to augment antibody-dependent cellular cytotoxicity, enabling coincident targeting of CD19 and additional antigens such as CD20
. FT596 also expresses IL-15RF, a potent cytokine complex that promotes survival, proliferation and trans-activation of NK cells and CD8 T cells without the need for systemic cytokine support.
These antibodies attack CD20
antigen on cancer cells, unlike conventional therapies.
Ofatumumab acts by complement-dependent and antibody-dependent cell-mediated cytotoxicity by binding to a small different epitope of CD20
, and is currently an approved intravenous drug for use in chronic lymphocytic leukemia (3).
is a cell surface marker that is expressed on B cell and presented during the stage of pre B cells.
Rituximab is a chimeric monoclonal antibody against CD20
, which is particularly expressed on the surface of B lymphocytes.
After cooling at room temperature, the slides were incubated with the following primary antibodies: ready to use CD20
mouse monoclonal antibody (Dako, Denmark,) for one hour to detect B cells and HSP70 mouse monoclonal antibody (Novocastra, UK) at a dilution of 1: 50 for 24 hours.
Considering higher positive expression of [CD19.sup.+], [CD20.sup.[+], CD79a.sup.+], [CD5.sup.+], and [CD43.sup.+] in MCL [41, 42], as well as the sizes of nanoparticles in our experiments, thus CD20
and CD5 antigens will be chosen as the target spots of specific nanoprobes.
Until recently, the phenotypic workup for HCL predominantly relied on flow cytometry, which allows targeted analysis of B-cell subpopulations (gating on CD19/CD20-positive B cells and allowing separation of B cells based on intensity of CD20
expression and on side/forward scatter properties).
Rituximab is a monoclonal antibody against CD20
antigen that is expressed in mature and immature B cells.
The gene encoding CD20
was invalidated in Raji cells using CRISPR/Cas9 genome editing .
(d) The RS-like B-cells have less prominent CD20
expression in comparison to the B-lymphocytes present in the polymorphous infiltrate.
Daudi cells as a CD20
expressing B-cell line were used to determine the Rituximab concentration and Octagam[R] instead of Rituximab as a negative control.